Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (262)

1

Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer

enthalten in: Cancer medicine | 2024

von Uekusa, R. | Yokoi, A. | Watanabe, E. | +9

2

Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction : A Case Report

enthalten in: In vivo (Athens, Greece) | 2024

von Endo, Y. | Kamo, N. | Kato, A. | +5

3

NRG-GY012 : Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

enthalten in: Cancer | 2024

von Rimel, B. | Enserro, D. | Bender, D. | +10

4

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2024

von Teng, Q. | Lei, Z. | Wang, J. | +9

5

TALAPRO-3 clinical trial protocol : phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

enthalten in: Future oncology (London, England) | 2024

von Agarwal, N. | Saad, F. | Azad, A. | +8

6

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer

enthalten in: International journal of technology assessment in health care | 2024

von Teppala, S. | Scuffham, P. | Tuffaha, H.

7

Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer

enthalten in: Gynecologic oncology | 2024

von Kim, J. | Kim, S. | Park, E. | +5

8

Promising Response of Olaparib in Patient With Germline ATM-Mutated Metastatic Gastric Cancer

enthalten in: Journal of investigative medicine high impact case reports | 2024

von Chan, K. | Rutazanaa, D. | Wray, C. | +3

9

Development of a simple high-performance liquid chromatography-ultraviolet detection method for olaparib in patients with ovarian cancer

enthalten in: Drug discoveries & therapeutics | 2024

von Yasu, T. | Nishijima, R. | Ikuta, R. | +2

10

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38) : a phase IIIb trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Pujade-Lauraine, E. | Selle, F. | Scambia, G. | +21

CommentOn: Ann Oncol. 2023 Dec;34(12):1074-1076. - PMID 38072509

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[27]